Firms will hone in on treatment of chronic inflammatory diseases.

LigoCyte Pharmaceuticals inked a partnership with Biogen Idec to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases.

CD103 is a alphaE-beta7 integrin that has been implicated in the activation, homing, and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.

LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for codevelopment, copromotion, and sharing of profits resulting from commercialized products.

Previous articleNovartis to Potentially Spend $500M on Osteoporosis Drug
Next articleCHDI to Leverage ActiveSight’s Fragment-Based Lead Discovery Know-How for Huntington’s